Showing results 1 - 3 of 3
At GJE our specialist and highly experienced biotech patent attorneys have a deep understanding of the commercial realities of the sector. We appreciate the strategic value of IP to a biotech company...
On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE...
We are delighted to announce that Ross Cummings and Ian Jones have joined the Partnership. Ross Cummings joined GJE in 2017, having previously worked at another top tier firm of patent and trade mark ...